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Sex Steroids, Insulin, and Arterial Stiffness in
Women and Men
Erik J. Giltay, Jan Lambert, Louis J.G. Gooren, Jolanda M.H. Elbers,
Mieke Steyn, Coen D.A. Stehouwer
Abstract—Arterial stiffness may be influenced by sex steroids and insulin; the association with fasting insulin level may
be stronger in women than in men. Therefore, we analyzed the effects of sex steroid administration on (1) arterial
stiffness and (2) the relationship between fasting insulin level and arterial stiffness. Twelve male-to-female transsexuals
were treated with ethinyl estradiol and cyproterone acetate, and 18 female-to-male transsexuals were treated with
testosterone esters, with assessments made at baseline and after 4 and 12 months. Changes in distensibility and
compliance coefficients (DC and CC, respectively) of the common carotid artery, femoral artery (FA), and brachial
artery (BA) were analyzed in relation to changes in fasting plasma levels of glucose, insulin, HDL-cholesterol, and
triglycerides. After 4 months of estrogens and antiandrogens in men, significant reductions in the CC and DC of the FA
(P50.006 and P50.04, respectively) and BA (P50.04 and P50.04, respectively) were observed. In women,
testosterone, on average, did not affect DC or CC, but the changes in fasting insulin level were strongly negatively
associated with changes in the CC and DC, especially in the FA and BA. These associations were significantly less
strong in genetic men and were independent of age, mean arterial pressure, and glucose and lipid levels. This
experimental study shows (1) that short-term administration of estrogens and antiandrogens increases FA and BA
stiffness in men and (2) that the fasting insulin level is a stronger determinant of arterial stiffness in women than in men.
(Hypertension. 1999;34:590-597.)
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Men are at a higher risk of developing cardiovasculardisease (CVD) than women, but in non–insulin-
dependent diabetes mellitus, this gender difference is much
less pronounced.1–4 A core element of non–insulin-dependent
diabetes mellitus is insulin resistance, and the question arises
of whether insulin resistance or other elements clustered in
the insulin resistance syndrome,5 such as hyperinsulinemia,
glucose intolerance, dyslipidemia, abdominal obesity, and
hypertension, partially negate the normal gender difference in
cardiovascular risk.
Large-artery stiffening, a major determinant of cardiac
workload and systolic blood pressure,6 may contribute to the
development of CVD. Data on a possible gender difference in
arterial stiffness are contradictory. Measurement of pulse-
wave velocity, an estimate of regional arterial stiffness,
indicates that arteries in men are stiffer than those in
premenopausal women.7–9 In contrast, local arterial stiffness
of the common carotid artery (CCA), measured by ultra-
sound,10–12 and global vascular stiffness, derived from pulse-
pressure waveform analysis,13 occur less in men than in
women. Conflicting data on the modulating effects of endog-
enous14 and exogenous15–20 estrogens on regional17–20 and
local arterial stiffness14–16 in women have also been pub-
lished. Currently, there is no prospective information on the
effects of estrogen or testosterone administration on arterial
stiffness in men or women.
Gender differences have been found in the interrelations
between fasting insulin level and arterial stiffness in cross-
sectional studies. A study of 4701 men and women showed
that an 80% increase in fasting insulin level was associated
with an increase of 5.1% in men and of 7.5% in women of
Young’s elastic modulus of the CCA, a measure of local
arterial stiffness controlled for wall thickness.21 In a previous
cross-sectional study, we found that fasting insulin level was
positively and glucose utilization was negatively associated
with arterial stiffness of the femoral artery (FA) in women but
not in men.12 In this study, we investigated prospectively (1)
the effects of cross-gender sex steroid administration on
arterial stiffness indices of the CCA, FA, and brachial artery
(BA) and (2) the influence of gender on the interrelationships
between arterial stiffness and elements of insulin resistance
syndrome.
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Methods
We included 14 white male-to-female (M3F) transsexuals (median
age, 26 years; range, 18 to 45 years) and 18 white female-to-male
(F3M) transsexuals (median age, 23 years; range, 17 to 40 years).
Baseline data of 24 of these subjects were reported previously.12
M3F transsexuals were treated with ethinyl estradiol (100 mg/d;
Lynoral, Organon) in combination with the antiandrogen cyprot-
erone acetate (100 mg/d; Androcur, Schering). F3M transsexuals
were treated with testosterone esters (250 mg every 2 weeks IM;
Sustanon, Organon). One F3M transsexual reported earlier intake
of oral contraceptives; all other F3M transsexuals had had regular
menstrual cycles (28 to 31 days) before cross-gender sex hormone
administration. There was no evidence of hypertension, CVD, or use
of other sex hormones. Eight M3F transsexuals and 12 F3M
transsexuals were smokers. Standardized radioimmunoassays were
used to measure serum levels of 17b-estradiol and testosterone.
Serum levels of luteinizing hormone (LH) and follicle-stimulating
hormone (FSH) were measured by immunometric luminescence
assays. Informed consent was obtained from all subjects, and the
study was approved by the Ethical Review Committee of the
University Hospital Vrije Universiteit.
Hemodynamic Measurements
The distensibility coefficient (DC), reflecting intrinsic vascular
wall elasticity, and the compliance coefficient (CC), reflecting
buffering capacity of the vessel wall, were calculated from the
arterial diameter (D) and changes in arterial diameter during the
heart cycle (dD; ie, distension) and pulse pressure (dP) as
follows: DC5(23dD)/(D3dP) and CC5(p3dD3D)/(23dP).
TABLE 1. Endocrine Variables and Vessel Wall Properties
Before and After 4 and 12 Months of Estrogen and
Antiandrogen Administration in M3F Transsexual Subjects
Baseline 4 mo 12 mo P
17b-Estradiol,
pmol/L
97611 * *
Testosterone,
nmol/L
2166 1.060.0 1.160.3 ,0.001
LH, IU/L 4.364.9 0.360.1 0.460.2 0.003
FSH, IU/L 6.3610.6 0.660.2 1.061.3 0.06
Heart rate, bpm 6566 73610 6965 0.001
Systolic blood
pressure, mm Hg
12069 122612 12069 0.31
Diastolic blood
pressure, mm Hg
6568 6569 6667 0.97
MAP, mm Hg 8668 8768 8568 0.34
Pulse
pressure, mm Hg
5466 5768 5466 0.22
CCA
D, mm 6.160.5 6.160.5 6.060.5 0.28
CC, mm2/kPa 0.8460.17 0.8060.17 0.7960.25 0.49
DC, 1023/kPa 29.366.7 28.168.1 27.566.4 0.59
FA (n59)
D, mm 7.361.2 7.361.2 7.161.2 0.24
CC, mm2/kPa 1.0060.24 0.7760.22 0.8060.30 0.045
DC, 1023/kPa 24.866.0 19.368.0 21.168.8 0.09
BA
D, mm 3.060.5 3.160.5 3.160.4 0.13
CC, mm2/kPa 0.2860.07 0.2460.06 0.2660.06 0.16
DC, 1023/kPa 42.8623.6 32.3615.7 36.3611.3 0.10
Body mass
index, m/kg2
20.462.9 21.262.7 21.463.0 ,0.001
Glucose, mmol/L 5.360.6 4.960.4 5.160.5 0.10
Insulin, pmol/L 43613 53613 56619 0.02
HDL-C, mmol/L 1.160.4 1.160.3 1.260.4 0.27
Triglycer-
ide, mmol/L
1.060.8 1.660.9 1.761.1 ,0.001
N512 unless otherwise indicated. Data are mean6SD. Only data on
complete sets during the 3 time points are presented. P values determined by
ANOVA for repeated measurements.
*Male3female transsexuals were treated with ethinyl estradiol, which is not
detected by the 17b-estradiol assay used.
TABLE 2. Endocrine Variables and Vessel Wall Properties
Before and After 4 and 12 Months of Androgen Administration
in F3M Transsexual Subjects
Baseline 4 mo 12 mo P
17b-Estradiol,
pmol/L
2126150 127633 131636 0.01
Testosterone,
nmol/L
1.660.5 26616 30614 ,0.001
LH, IU/L 4.762.1 2.462.1 2.161.7 ,0.001
FSH, IU/L 4.661.1 4.061.6 3.361.9 0.04
Heart rate, bpm 69610 67612 6867 0.83
Systolic blood
pressure, mm Hg
11469 11469 116612 0.63
Diastolic blood
pressure, mm Hg
6266 6166 6167 0.58
MAP, mm Hg 8267 8068 8268 0.56
Pulse
pressure, mm Hg
5266 5465 5566 0.054
CCA (n517)
D, mm 5.760.4 5.660.4 5.760.4 0.25
CC, mm2/kPa 0.7560.16 0.6760.11 0.7360.13 0.14
DC, 1023/kPa 29.565.0 27.364.2 28.965.4 0.32
FA (n517)
D, mm 6.660.7 6.860.7 6.860.7 0.04
CC, mm2/kPa 0.7960.27 0.7460.18 0.8060.21 0.44
DC, 1023/kPa 24.0610.0 21.067.4 23.068.4 0.22
BA (n517)
D, mm 2.660.4 2.860.4 2.860.4 0.01
CC, mm2/kPa 0.1960.06 0.1960.07 0.1960.05 0.89
DC, 1023/kPa 38.7615.9 32.5613.4 33.5613.3 0.09
Body mass
index, m/kg2
23.765.2 24.764.9 24.564.5 0.001
Glucose, mmol/L 4.960.6 4.360.7 4.860.6 0.001
Insulin, pmol/L 55630 49623 52625 0.55
HDL-C, mmol/L 1.360.3 1.060.2 1.060.2 ,0.001
Triglycer-
ide, mmol/L
0.860.5 0.960.4 0.960.4 0.52
N518 unless otherwise indicated. Data are mean6SD. Only data on
complete sets during the 3 time points are presented. P values determined by
ANOVA for repeated measurements.
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All hemodynamic measurements were performed with use of a
noninvasive ultrasound system as previously described11,12,22,23
after at least 15 minutes of supine rest in a temperature-
controlled, quiet room. All subjects refrained from smoking or
consuming caffeine for at least 4 hours before examination. The
within-subject coefficients of variation for DC and CC are 7.7%
and 8.3%, respectively, for the CCA; 13.4% and 12.5%, respec-
tively, for the FA; and 16.1% and 15.6%, respectively, for the
BA.22,23 The systolic, diastolic, pulse, and mean arterial pressure
(MAP) were assessed 4 times at 5-minute intervals with an
automatic oscillometric device (BP-8800, Colin) and then aver-
aged. Twelve-month measurements were not obtained in 2 M3F
transsexuals, and some other measurements could not be obtained
successfully for practical reasons (detailed in Tables 1 to 3).
Elements Clustered in the Insulin
Resistance Syndrome
Fasting blood samples were obtained in all subjects to measure plasma
levels of glucose, insulin (using a immunoradiometric assay, Biosource
Diagnostics), HDL cholesterol (HDL-C), and triglycerides (using enzy-
matic colorimetric methods, Boehringer Mannheim). Body mass index
was assessed (weight/height2), and lean body mass and total body fat
were estimated using bioelectrical impedance analysis (BIA 101/S, RJL
Systems). Body circumferences were measured in duplicate to calculate
the waist-to-hip ratio. Areas of abdominal subcutaneous and visceral fat
(using a magnetic resonance imaging technique) and glucose utilization
rate (M [expressed as mg glucose/kg lean body mass z min]; with a
2-hour hyperinsulinemic euglycemic clamp) were assessed in 9 M3F
and 12 F3M transsexuals at baseline and after 12 months as previously
described.12
Statistical Analysis
Variables with skewed distributions (abdominal subcutaneous fat
area and plasma levels of insulin and triglycerides) were logarithmi-
cally transformed before analysis to normalize their distributions.
Student’s t test for independent and paired samples was used to
compare differences between men and women and between different
artery sites. In the M3F and the F3M groups (analyzed separate-
ly), an ANOVA for repeated measurements was used to analyze the
effects of cross-gender sex hormones. Interaction terms were in-
cluded in an ANOVA to test whether the effects of cross-gender sex
hormones on the CC and DC differed between genetic men and
women. An ANCOVA for repeated measurements was used to
analyze the influence of elements clustered in the insulin resistance
syndrome on hemodynamic measurements at the 3 time points (with
e2 as the measure of effect size). Univariate and bivariate linear
regression analyses were used to explore interrelationships between
proportional changes, at 4 months, of hemodynamic measurements
and elements clustered in the insulin resistance syndrome. Interac-
tion terms of genetic gender and insulin changes were included in
linear regression analyses to test whether the associations of the
proportional changes of hemodynamic measurements and fasting
insulin levels differed between genetic men and women. If a value
was below the lower limit of detection, that value was used for
statistical calculations (for LH, 0.3 IU/L; FSH, 0.5 IU/L; 17b-
estradiol, 90 pmol/L; and testosterone, 1.0 nmol/L). P,0.05 (2-way)
was considered statistically significant. The software used was SPSS
for Windows, version 8.0.
Figure 1. Plots showing the DC and CC (with bars representing SEM) of the CCA, FA, and BA at baseline and after 4 and 12 months in 12
M3F transsexuals receiving estrogens and antiandrogens and 18 F3M transsexuals receiving androgens. After 4 months of estrogen and
antiandrogen administration, significant reductions, as compared with baseline, of CC and DC of the FA and BA were found. Interaction anal-
ysis showed that estrogenic and androgenic effects were not significantly different. *P,0.05 (paired sample t test comparing baseline and
4-month values). †P,0.05 (ANOVA for repeated measurements comparing baseline and 4- and 12-month values).
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Results
Pretreatment Values
All subjects were eugonadal at baseline according to
clinical and laboratory criteria. D and CC of the BA were
statistically significantly larger in men than in women
(P50.009 and P50.001, respectively). No significant
gender differences were found in other hemodynamic
measurements, nor in smoking status, body mass index,
and plasma levels of glucose, insulin, triglyceride, and
HDL-C (Tables 1 and 2).
Effects of Cross-Gender Sex
Hormone Administration
After estrogen and antiandrogen administration to M3F
transsexuals, serum levels of testosterone, LH, and FSH
decreased (Table 1). In M3F transsexuals, 4 months of
Figure 2. Scatter plots showing the association between the proportional changes, at 4 months vs baseline, of plasma insulin levels
and those of dD, CC, and DC. Univariate regression lines in 14 M3F and in 18 F3M transsexuals are given. Interaction terms in linear
regression analyses showed that the effects of cross-sex hormones in genetic men and women were all significantly different. When the
1 M3F transsexual and the 1 F3M transsexual with a proportional change in fasting insulin level .50% were excluded from the anal-
yses, interaction terms were still statistically significant determinants for DC of the CCA and for dD, CC, and DC of the FA (for all,
P,0.05), and there was a statistical trend for CC of the BA (P50.07).
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administration of estrogens and antiandrogens, as compared
with baseline, was associated with significant reductions of
dD, CC, and DC of the FA (P50.02, P50.006, and P50.04,
respectively) and BA (P50.01, P50.04, and P50.04, respec-
tively; Figure 1) and a significant increase in heart rate
(P50.005; Table 1). The proportional changes, at 4 months,
in dD of the FA and BA were significantly different than the
change in dD of the CCA (P50.047 and P50.01, respective-
ly), whereas changes in dD were similar for the FA and BA
(P50.85). The proportional changes, at 4 months, in heart
rate were not significantly associated with any proportional
change of the DC or CC of the CCA, FA, and BA, except for
the DC of the FA (b5 20.64, P50.04). After 12 months, the
CC of the FA remained significantly decreased (P50.03;
Figure 1) and heart rate remained significantly increased
(P50.02) as compared with baseline values. No significant
changes were seen in D values (Table 1).
After testosterone administration to F3M transsexuals,
the serum testosterone level increased markedly, whereas
serum levels of 17b-estradiol, LH, and FSH decreased only
slightly (Table 2). The CC and DC of the CCA, FA, and BA
did not change significantly over time (Figure 1). The D
values of the FA and BA increased significantly after 4 and
12 months of androgen administration in an ANOVA for
repeated measurements (Table 2). Interaction terms in an
ANOVA for repeated measurements showed that the effects
on CC and DC did not differ significantly between adminis-
tration of estrogens1antiandrogens or androgens (for all,
P$0.23; Figure 1), except for the CC of the FA, which tended
to decrease in genetic men as compared with genetic women
(P50.07).
Associations With Elements Clustered in the
Insulin Resistance Syndrome
Table 3 shows the associations between proportional changes,
at 4 months, of D, CC, and DC with proportional changes of
elements clustered in the insulin resistance syndrome. The
proportional change of fasting insulin level was the most
robust determinant of the proportional changes of dD, CC,
and DC, with positive associations in M3F transsexuals and
negative associations in F3M transsexuals (Table 3 and
Figure 2). Interaction analysis showed that these associations
differed significantly between the genetic sexes (Figure 2).
Associations of proportional changes of insulin level with
those of the CC and DC of the FA in M3F transsexuals and
with those of the CC and DC of the FA and the CC of the BA
in F3M transsexuals were independent of smoking status,
age, and proportional changes of MAP, body mass index, and
glucose, HDL-C, and triglyceride levels. To establish this,
several bivariate regression analyses were performed with
proportional changes of the CC or DC as the dependent
variable and with proportional changes of fasting insulin level
combined with each of the possible confounding variables as
the 2 independent variables.
When both the M3F and F3M transsexuals with a
proportional change in fasting insulin level .50% (Figure 2)
were excluded from the analyses, the results were similar:
Proportional changes in fasting insulin level were still posi-
TABLE 3. Associations Between Proportional Changes, of 4 Months versus baseline, of D, CC, and DC and Proportional Changes of
Elements Clustered in the Insulin Resistance Syndrome
CA FA
n D, % CC, % DC, % n D, % CC, % DC, %
M3F transsexuals
MAP, % 14 0.10 (0.72) 0.16 (0.59) 0.13 (0.67) 11 0.71 (0.01) 20.39 (0.24) 20.48 (0.13)
Glucose, % 13 20.32 (0.28) 0.39 (0.19) 0.49 (0.09) 10 0.37 (0.29) 0.06 (0.86) 20.02 (0.95)
Insulin, % 14 20.08 (0.78) 0.61 (0.02) 0.59 (0.03) 11 20.19 (0.58) 0.75 (0.008) 0.73 (0.01)
HDL-C, % 14 0.08 (0.79) 20.11 (0.70) 20.12 (0.68) 11 20.01 (0.98) 0.37 (0.27) 0.33 (0.32)
Triglyceride, % 14 20.28 (0.34) 0.79 (0.001) 0.80 (0.001) 11 0.07 (0.83) 0.10 (0.76) 0.07 (0.83)
Body mass index, % 14 20.21 (0.48) 0.46 (0.10) 0.47 (0.09) 11 20.21 (0.53) 20.12 (0.73) 20.07 (0.85)
Waist-to-hip ratio, % 11 20.28 (0.40) 0.32 (0.33) 0.38 (0.25) 9 0.36 (0.34) 20.19 (0.63) 20.25 (0.52)
Lean body mass, % 11 20.02 (0.95) 0.36 (0.28) 0.31 (0.35) 9 0.35 (0.36) 20.57 (0.11) 20.58 (0.10)
Total body fat, % 11 20.31 (0.35) 0.39 (0.24) 0.46 (0.16) 9 20.49 (0.19) 0.60 (0.09) 0.64 (0.07)
F3M transsexuals
MAP, % 18 20.33 (0.18) 20.49 (0.04) 20.48 (0.045) 18 20.05 (0.84) 20.40 (0.10) 20.41 (0.09)
Glucose, % 18 0.01 (0.99) 20.17 (0.49) 20.20 (0.44) 18 20.30 (0.23) 20.05 (0.85) 0.04 (0.89)
Insulin, % 18 20.40 (0.10) 20.57 (0.02) 20.55 (0.02) 18 20.24 (0.33) 20.70 (0.001) 20.64 (0.005)
HDL-C, % 18 0.10 (0.70) 0.06 (0.83) 0.02 (0.94) 18 20.03 (0.89) 20.17 (0.50) 20.17 (0.51)
Triglyceride, % 18 20.04 (0.89) 20.21 (0.42) 20.20 (0.43) 18 20.07 (0.78) 20.20 (0.44) 20.17 (0.50)
Body mass index, % 18 0.07 (0.77) 0.18 (0.47) 0.19 (0.45) 18 20.03 (0.90) 0.22 (0.38) 0.25 (0.31)
Waist-to-hip ratio, % 13 20.02 (0.95) 20.18 (0.56) 20.18 (0.55) 13 0.29 (0.34) 20.04 (0.89) 20.18 (0.55)
Lean body mass, % 13 20.05 (0.86) 0.28 (0.35) 0.31 (0.31) 13 20.18 (0.55) 0.56 (0.048) 0.62 (0.03)
Total body fat, % 13 20.02 (0.96) 20.28 (0.36) 20.27 (0.37) 13 20.04 (0.89) 20.13 (0.66) 20.09 (0.78)
Values are standardized regression coefficients (b), with P value between brackets, determined with univariate regression analysis.
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tively associated with those of the CC of the FA (b50.64,
P50.048) in M3F transsexuals and negatively associated
with those of the CC and DC of the FA (b520.72, P50.001
and b520.64, P50.006, respectively) and of the CC of the
BA (b520.56, P50.02) in F3M transsexuals.
ANCOVA of values at baseline and after 4 and 12 months
of cross-gender sex hormone administration was used to
analyze the variability in DC and CC explained by the fasting
insulin level. In M3F transsexuals, fasting insulin level
significantly determined the variability of the CC and DC of
the CCA (e250.25, P50.04 and e250.35, P50.003, respec-
tively). In F3M transsexuals, fasting insulin level signifi-
cantly determined the variability of the CC of the CCA
(e250.15, P50.02), CC and DC of the FA (e250.27,
P50.002 and e250.15, P50.03, respectively), and CC and
DC of the BA (e250.35, P,0.001 and e250.29, P50.001,
respectively). Visual interpretation of relationships between
fasting insulin level and the CC and DC indicated that these
were largely positively related in genetic men and inversely
related in genetic women, both before and during hormone
administration (data not shown).
With the use of ANCOVA, we also analyzed whether the
variability of D, DC, or CC could be explained by glucose
utilization, the abdominal subcutaneous fat area, or the
visceral fat area. None of these covariables could signifi-
cantly explain the variability of the hemodynamic measure-
ments of the CCA, FA, or BA (data not shown).
Discussion
We prospectively studied the effects of cross-gender sex
steroid administration on arterial stiffness indices in healthy
women and men. Because of the heterogeneity of the arterial
tree, we studied 3 sites. On the basis of the elastin, collagen,
and smooth muscle content in the vessel wall, the CCA is
regarded as an elastic vessel, whereas the FA and BA are
regarded as muscular vessels.6 Our findings suggest that
administration of high-dose estrogens and antiandrogens to
young men may have short-term deteriorating effects on FA
and BA compliance and distensibility. Estrogenic effects on
arterial stiffness may partly account for the somewhat in-
creased short-term risk of CVD associated with relatively
high-dose estrogen administration in men with prostate can-
cer24 or myocardial infarction.25 In addition, administration of
estrogens and progestogens to postmenopausal women with26
or without27 coronary disease does not decrease and may even
increase the short-term risk of CVD, which contradicts
epidemiological data.28 In genetic women, we found that
androgen administration did not affect arterial stiffness,
whereas the D of the FA and BA increased, which may be an
adaptation to increased water retention29 and muscle mass.
An increased muscle mass might affect the D of the FA and
BA more than that of the CCA, because the FA and BA
supply blood to muscular territories.
In previous cross-sectional studies, postmenopausal estro-
gen replacement therapy was associated with higher CCA
distensibility15,16 and lower aortofemoral and leg pulse-wave
velocity,18 whereas no differences were found in brachial and
aortodorsalis pulse-wave velocity19 and CCA distensibility16
with estrogen-progesterone combination therapy. Further-
more, natural fluctuations of estrogen levels during the
menstrual cycle did not influence the CC and DC of the CCA
and FA,14 and long-term use of the synthetic steroid tibolone
did not influence aortic pulse-wave velocity.17 A longitudinal
study showed that short-term withdrawal of estrogen-
containing therapy, either alone or combined with progester-
one, in postmenopausal women decreased systemic arterial
compliance and increased leg pulse-wave velocity, both of
which were restored to baseline values after reinstitution of
therapy.20
At baseline, we found a higher CC in men than in women,
which was significant for the BA and nonsignificant for the FA
and CCA (48%, 27%, and 13%, respectively) and which may
have been due to the relatively larger D that is part of the
numerator of the equation for CC (Tables 1 and 2). Larger artery
calibers and a lower heart rate13 in men as compared with
women may be related to the greater body height of men.12,30
Possible Determinants of Changes in
Arterial Stiffness
The mechanism of action of sex steroids on arterial stiffness
is not well understood. First, estrogens could act directly on
vascular smooth muscle and endothelial cells, which contain
estrogen receptors.31,32 Second, estrogens,33 like androgens,29
increase body water retention. Estrogens also increase argi-
nine vasopressin release,33 myocardial contractility, and
stroke volume34 and, in our subjects, increased heart rate.
This possibly reduced stroke volume as well as the time
interval in which the pulsatile pressure expands the arterial
wall. Because of the dynamic viscoelastic properties of the
vessel wall, the maximum increase in D falls as a conse-
TABLE 3. Continued
BA
n D, % CC, % DC, %
14 20.38 (0.18) 0.09 (0.77) 0.29 (0.32)
13 20.16 (0.60) 0.60 (0.03)* 0.62 (0.03)*
14 0.05 (0.87) 0.45 (0.11) 0.36 (0.21)
14 0.26 (0.37) 0.27 (0.34) 0.09 (0.76)
14 0.19 (0.52) 0.32 (0.27) 0.16 (0.58)
14 0.03 (0.91) 0.28 (0.33) 0.23 (0.43)
11 0.06 (0.86) 0.32 (0.34) 0.30 (0.38)
11 0.24 (0.47) 0.35 (0.29) 0.18 (0.60)
11 0.05 (0.89) 0.30 (0.37) 0.25 (0.45)
17 0.06 (0.82) 20.34 (0.18) 20.33 (0.20)
17 20.22 (0.41) 0.07 (0.80) 0.13 (0.62)
17 20.00 (1.00) 20.61 (0.009)* 20.53 (0.03)*
17 0.37 (0.15) 20.07 (0.79) 20.24 (0.36)
17 20.52 (0.03)* 20.20 (0.44) 0.11 (0.67)
17 0.25 (0.34) 0.35 (0.17) 0.15 (0.56)
13 20.13 (0.68) 20.22 (0.46) 20.14 (0.65)
13 0.60 (0.03)* 0.58 (0.04)* 0.15 (0.63)
13 20.32 (0.28) 20.02 (0.95) 0.25 (0.41)
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quence of increased heart rate. This could have led to a
decreased dD value at 4 months, as was found in the FA and
BA. In anesthetized rats, it has been shown that acute
increases in heart rate are accompanied by reductions in
arterial compliance and distensibility.35
Third, the effects may be mediated by an action on insulin
sensitivity or circulating insulin. Estrogens may induce insu-
lin resistance36 and, in our subjects, increased the fasting
insulin level, which is a fair marker of insulin resistance
among subjects with normal glucose tolerance.37 We previ-
ously concluded that arterial stiffening in women is positively
associated with fasting insulin levels or insulin resistance,12
which is supported by the present experimental data. Insulin
resistance may lead to a disturbance of cellular cation
transport (or be a marker thereof), which may promote
vasoconstriction and arterial stiffening,38 affecting the mus-
cular FA and BA more than the elastic CCA. However,
insulin may also directly affect the vessel wall. Insulin
induces hypertrophy of vascular smooth muscle in vitro39;
insulin receptors have been found in the arterial wall40; and
CCA wall thickness, which is inversely associated with CCA
distensibility,16 is positively related to insulin level in vivo.41
The contrasting associations in men and women between
fasting insulin level and arterial stiffness suggest that being a
genetic woman (ie, the presence of 2 X chromosomes)
determines the relationship between fasting insulin level and
arterial stiffness. Alternatively, the presence of circulating
estrogens, which were not substantially reduced in genetic
women (cf Table 2), may be the basis for the stronger
relationship between fasting insulin level and arterial stiffness
in women than in men. Our findings may be relevant to the
observation that diabetic women, as compared with diabetic
men, are at a relatively higher risk of developing CVD1,2 and
have a worse prognosis after myocardial infarction.3,4
Limitations and Strengths of Study
Our analyses were limited by the fact that because of the
nature of the treatment indication, we could include only
relatively small numbers of subjects, did not include a control
group, and used an open study design. However, a regression
toward the mean effect seems unlikely with regard to the
effects on FA and BA stiffness in men treated with estrogens
and antiandrogens, because shifts in FA and BA distension
differed significantly from those of the CCA. Local pulse
pressure was not measured, but BA pulse pressure did not
appear to modulate the association between fasting insulin
level and arterial stiffness, as illustrated by the significantly
stronger associations in women than in men between shifts of
fasting insulin level and locally measured dD (not corrected
for dP and D). We applied statistical analyses many times by
including several covariates, without correcting for their
multiplicity. However, our main finding, the association
between fasting insulin level and arterial stiffness, was
strong, consistent in the 2 muscular arteries, robust during
and after sex steroid challenges, and significantly different
between the genetic sexes. Moreover, this is, to the best of our
knowledge, the first report from an experimental study of the
stronger association in women than in men between muscular
artery stiffness and fasting insulin level, which has been
reported in cross-sectional studies.12,21
Conclusions
Estrogen and antiandrogen administration for 4 months in-
creases FA and BA stiffness in men, whereas the effects wear
off somewhat after 12 months. In women, testosterone
administration did not affect CC or DC, but the proportional
changes of fasting insulin level were strongly negatively
associated with the proportional changes of CC and DC.
These associations were consistent in the FA and BA, were
significantly less strong in genetic men, and were indepen-
dent of age, MAP, and glucose and lipid levels. Fasting
insulin level in the presence of estrogens may be a stronger
determinant of arterial stiffness in women than in men.
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